Abstract
preparation of the CpG-Hlp complex was performed as previously described [12] . 170
In the case of in vitro treatment with thalidomide (Abcam, CB, UK), the drug was 171 dissolved in DMSO (Sigma-Aldrich, MO, EUA) and used at a final concentration 172 of 50 µg/ml. NETs were quantified in the culture supernatant via the Quant-iT™ 173
PicoGreen® dsDNA Assay kit (Thermo Fisher Scientific, MA, USA) according to 174 the manufacturer's instructions. In vitro thalidomide efficacy was tested in human 175 monocytes stimulated with LPS (Sigma-Aldrich), as previously described [16] . 176
177
Immunofluorescence 178
Immunofluorescence staining in frozen skin tissue was performed, as 179 previously described [12] . For in vitro immunofluorescence staining, neutrophils 180 (2x 10 6 ) were incubated in 24-well plates, adhered to poly-L-lysine-coated 181 coverslips (1:10, Sigma-Aldrich), with or without MLWCS or CpG-Hlp, for 90 min 182 and fixed with 4% paraformaldehyde. NETs were evidenced by DAPI (Sigma recruited upon leprosy diagnosis and before initiating MDT. T2R patients were 240 enrolled in the study at diagnosis of reaction and initiation of thalidomide 241 treatment. Fifteen T2R patients were reassessed at day 7 of treatment (T2Rthal). 242
Healthy donors (HD) participated in a variety of assays during the study. 243
In most cases, the severe inflammatory process triggered during T2R 244 leads to neutrophil infiltration [8] . Thus, as a first step, the presence of NETs in 245 the skin lesions of T2R patients along with the potential effect of thalidomide on 246 the abundance in NETs production were analyzed. Biopsies stained with H&E 247 confirmed the classical presence of an important inflammatory neutrophil infiltrate 248 in the T2R lesion, which, importantly, was drastically reduced by day 7 of 249 treatment (T2RThal) (S1 Fig). The lesions, labeled for NETs detection by 250 immunofluorescence, utilized myeloperoxidase (MPO), histone H1, and DNA as 251 12 markers. The co-localization of these molecules in filamentous structures 252 characterizes NETs. It was observed that the intense NETs production detected 253 in T2R patient skin lesions essentially disappeared as a result of thalidomide 254 treatment ( Fig 1A) . 255
Circulating NETs-derived components have been demonstrated in 256 several inflammatory diseases in which NETosis has been implicated in their 257 pathogenesis [18] [19] [20] . The levels of MPO-or histone-DNA complexes in the 258 serum of T2R patients were then investigated via specific immune enzymatic 259 assays. A trend toward higher levels of the serum DNA-MPO complex was 260 observed in T2R patients than those among non-reactional LL/BL (Fig 1B) . 261
Moreover, a longitudinal follow-up of 10 T2R patients showed a reduction in 262 DNA-MPO complex levels in 7 of these patients at day 7 of treatment (T2Rthal) 263 (Fig 1C) . Healthy donors presented lower levels of this complex, at a median 264 value of 6.780% (IIQ: 0% -54.64%; n=15), in relation to the blank. In confirmation 265 of our previous data [12], significantly higher human DNA-histone complex levels 266 were found in T2R than in LL/BL patients ( Fig 1D) . In addition, these same 7 out 267 of the 10 T2R patients showed lower levels of this complex at day 7 of treatment 268 (Fig 1E) . The levels of this complex in healthy donors, however, were similar to 269 LL/BL patients, higher levels of released DNA were detected in a T2R subgroup 295 (Fig 2A) . Interestingly, among the 7 patients with the highest DNA values, 5 296 developed reaction during MDT (red dots). Indeed, when this group was 297 compared with the T2R patients who developed reaction before or after MDT, a 298 significant difference was observed between them ( Fig 2B) . All T2R patients with 299 the highest DNA levels showed reduced DNA release after 7 days of thalidomide 300 medication (Fig 2C) . Spontaneous ex vivo NETs formation was confirmed by 301 fluorescence microscopy in neutrophils isolated from T2R patients as well as the 302 reduction of NETs production upon administration of thalidomide (Fig 2D) . This 
vitro. 335
Consequently, the ability of MLWCS to induce NETs production in 336 leprosy patient peripheral neutrophils was then examined. MLWCS stimulated 337 the neutrophils of all 3 groups of patients to release DNA at higher levels than in 338 the non-stimulated cultures (Fig 3A) . NETs formation in response to MLWCS in 339 neutrophils of leprosy patients was confirmed by immunofluorescence (Fig 3B) . The apparently in vivo inhibitory effect of thalidomide on NETs 354 production in T2R patients observed both at the lesion site ( Fig 1A) and in 355 peripheral neutrophils (Fig 2) raised the hypothesis that the drug might be acting 356 directly in this process. As a test, healthy-donor neutrophils were stimulated in 357 vitro with MLWCS in the presence or not of thalidomide while NETs production 358 was monitored by DNA release. S4A Fig shows the results obtained with one  359 donor, in which no effect of thalidomide on MLWCS-induced NET formation was 360 observed. S4B Fig summarizes the results of 6 healthy donors, only one of whom 361 experienced an inhibitory effect. As expected, however, thalidomide was able to 362 block TNF secretion by monocytes in response to LPS, as previously referred to 363
[16] (S4C Fig). The incapacity of thalidomide to directly interfere in the NETs 364 production process is reinforced by the observation that T2Rthal neutrophils 365 continued to respond to MLCWS in vitro even after receiving in vivo thalidomide 366 (Figs 3A and 4A ). These data suggest that the inhibitory in vivo effect of 367 thalidomide on NETs formation is, albeit indirectly, most probably related to the 368 capacity of this drug to block pro-inflammatory cytokine production such as IFN-I 369
[24], a mediator known to prime neutrophils to NETosis [25] . 370
TLRs had been previously implicated in NETosis induction [23] . In our 371 previous study, besides the higher levels of endogenous histone-DNA 372 complexes, higher levels of the mycobacterial histone-like protein (Hlp) in T2R 373 patients sera, probably released as a consequence of bacterial killing during 374 MDT [12], was also detected. Thus, we hypothesized that Hlp complexed to 375 DNA, a TLR9 ligand, could be one of the bacterial components present in 376 MLWCS that is responsible for NETs induction. To test this hypothesis, 377 recombinant Hlp was obtained and then combined with the CpG oligonucleotide, 378 mimicking bacterial DNA. Neutrophils were then stimulated with the CpG-Hlp 379 complex for 90 min; and NETs production was monitored by measuring DNA 380 release in culture supernatants. CpG-Hlp was shown to induce NET formation in 381 vitro in leprosy patient neutrophils at levels comparable to those seen for 382 MLWCS (Fig 4A) . The capacity of CpG-Hlp to stimulate NETs production in 383 leprosy patients was confirmed by immunofluorescence (Fig 4B) . 384
We have previously demonstrated higher expression levels of TLR9 in 385 skin lesions and T2R blood mononuclear cells as opposed to LL/BL patient levels 386
[12]. Thus, as a next step, the status of TLR9 expression in leprosy patient 387 neutrophils was compared. The median fluorescence intensity (MFI) values of 388 TLR9 in T2R neutrophils were higher overall relative to those of LL/BL patients. 
